Study selection Studies were included if they were randomised trials that compared oral appliance (OA) with control or other treatments in adults who had sleep apnoea. Data extraction and synthesis Trial quality was assessed and two reviewers extracted data independently. Study authors were contacted for missing information. Results Twelve trials were included, involving 509 participants. All the studies had some methodological shortcomings. Overall, OA use improved the apnoea-hypopnoea index (AHI) more than inactive control. The AHI for the former was À13.17 (95% confidence interval (CI), À18.53 to À7.80) in parallel group data from four studies. Use of an OA reduced daytime sleepiness in two trials, giving a weighted mean difference (WMD) of À1.77 (95% CI, À2.91 to À0.62). OA use was less effective than continuous positive pressure in reducing the AHI (respectively giving a WMD of 13 (95% CI, 7.63À18.36) in parallel studies from two trials and of 6.75 (95% CI, 4.93À8.57) in crossover studies from six trials). No significant difference was observed on symptom scores (data from three trials), however.
Commentary
The review on the use of OA for obstructive sleep apnoea states that, although both OA and nCPAP can effectively treat Obstructive Sleep Apnoea and Hypopnoea Syndrome (OSAHS), nCPAP is the most predictable method and would routinely be the preferred choice for clinicians. Nevertheless, a significant clinical consideration is that, whereas nCPAP may be able to ablate apnoeas for virtually all patients, many individuals do not tolerate its use. Thus, OA use can frequently be very effective for people unable or unwilling to adjust to nCPAP. Some patients do not desire, or are incapable of adapting to, regular use of nCPAP because of reasons ranging from discomfort from mask leaks, claustrophobia, travel or even social reasons. This leaves two alternatives: various surgical interventions (eg, uvulopalatopharyngoplasty) with their morbidity, or OA use.
A significant population of people who are intolerant to nCPAP are unwilling to undergo surgery (or who have had surgical failures) but still require treatment. The use of an OA, mostly mandibular advancement devices, is a relatively non-invasive and frequentlyeffective treatment to use for these otherwise difficult-to-manage cases. Treatment should not be withheld because a person cannot adapt to nCPAP. Papers quoted in the review point out that many patients are adequately managed by OA, and there are instances (even when the device is less effective than nCPAP) when the patient preferred OA to nCPAP.
Anecdotally, I can report on a tertiary medical facility at which OA use became an option. Patients referred to the dental clinic (in this case at a military installation) with OSAHS were solely those who were intolerant of nCPAP, had already experienced failed surgery or were poor risks for surgical therapy. All had pre-and post-operative polysomnography (PSG) and results were tabulated to determine if OA was a viable option. By the end of 18 months the regimen was altered so that all but the most severely affected patients were offered either OA or nCPAP. All had the choice to crossover if they desired, but it was a rare patient who had a satisfactory post-operative PSG after OA use who changed to nCPAP: others participants did the reverse, however.
Some dental practitioners who provide OA are seeing tooth movement in as many as 10% of long-term cases. To a dentist, changes of this nature are major issues but it is extremely difficult to convince a patient to give up their OA. To them, their otherwise untreatable OSAHS symptoms far outweigh the dental complications.
Practice point
OA should be the first choice of treatment. There are feasible alternatives for patients who cannot be managed with nCPAP.
